Cellular Biomedicine Group (NASDAQ: CBMG) is one of 298 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Cellular Biomedicine Group to similar businesses based on the strength of its institutional ownership, profitability, analyst recommendations, valuation, dividends, earnings and risk.
Valuation and Earnings
This table compares Cellular Biomedicine Group and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Cellular Biomedicine Group||$630,000.00||-$28.20 million||-6.22|
|Cellular Biomedicine Group Competitors||$290.00 million||$35.57 million||150.28|
Volatility & Risk
Cellular Biomedicine Group has a beta of 2.61, indicating that its share price is 161% more volatile than the S&P 500. Comparatively, Cellular Biomedicine Group’s peers have a beta of 0.92, indicating that their average share price is 8% less volatile than the S&P 500.
This is a summary of recent ratings and price targets for Cellular Biomedicine Group and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cellular Biomedicine Group||0||0||1||0||3.00|
|Cellular Biomedicine Group Competitors||785||3126||11381||228||2.71|
Cellular Biomedicine Group presently has a consensus target price of $18.00, indicating a potential upside of 68.22%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 41.49%. Given Cellular Biomedicine Group’s stronger consensus rating and higher possible upside, equities analysts plainly believe Cellular Biomedicine Group is more favorable than its peers.
Institutional and Insider Ownership
5.8% of Cellular Biomedicine Group shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 8.2% of Cellular Biomedicine Group shares are owned by company insiders. Comparatively, 16.5% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Cellular Biomedicine Group and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cellular Biomedicine Group||-7,579.14%||-42.56%||-40.22%|
|Cellular Biomedicine Group Competitors||-5,110.46%||-418.25%||-40.67%|
Cellular Biomedicine Group Company Profile
Cellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases.
Receive News & Ratings for Cellular Biomedicine Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.